Audited Financial Results as on 31st March 2026.
NATHBIOGEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Nath Bio-Genes reported FY 2025-26 revenue of Rs 4,316 crore, up 19.1% from Rs 3,623 crore in the prior year. Net profit grew 5.4% to Rs 444.26 lakh from Rs 421.40 lakh. However, EBITDA margin compressed from ~13.4% to ~11.3% due to rising production expenses. The company declared a dividend of Rs 2 per share (20%). The auditor issued an unmodified (clean) opinion but included an Emphasis of Matter noting recovery of Rs 600.73 lakh against previously provisioned advances to farmers, and pending confirmations on certain receivables, payables and loans. Operating cash flow turned negative at Rs -139.14 lakh due to inventory build-up and working capital changes.
Positive revenue momentum but margin compression is a concern. Clean audit with no going concern issues is reassuring. The negative operating cashflow and large outstanding income tax disputes (totaling Rs 6,610 lakh across multiple years) warrant attention.